Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data
Figure 2
Pharmacology of intraoperative intraperitoneal gemcitabine in a patient with resected pancreas cancer. The drug was used at 1,000 mg/m2 in 3 liters of 1.5% dextrose peritoneal dialysis solution administered intraperitoneally. The area under the curve ratio of concentration × time intraperitoneal to intravenous was 210. Sixty-eight percent of the drug was cleared from the peritoneal cavity in 60 minutes. Data were taken from the study of a single patient but are similar to those in four other patients. The patient has completed the long-term intraperitoneal gemcitabine without incident.
